Genotype CC of rs1800947 in the C-Reactive Protein Gene May Increase Susceptibility to Colorectal Cancer: a Meta-Analysis

  • Chen, Xiao-Lin ;
  • Liao, Yong-Qiang ;
  • Liu, Jian-Rong
  • Published : 2014.03.30


Background: Single nucleotide polymorphisms of C-reactive protein (CRP) have been shown to be related to circulating CRP level, risk and prognosis in cancer patients. However, accumulating evidence of rs1800947 involvement in risk of cancer is inconsistent. Thus, a meta-analysis was performed to obtain a more precise relationship. Materials and Methods: The pooled odds ratio (OR) and its 95% confidence interval were assessed in 10 eligible articles with 12 studies containing 5,601 cancer cases and 8,669 cancer-free controls. Results: No significant association was observed overall and in subgroups in comparison of genotype GC vs GG ($P_H$=0.847, OR=0.939, 95%CI=0.810-1.087), GC/CC vs GG ($P_H$=0.941, OR=1.021, 95%CI=0.901-1.157) and allele C vs G ($P_H$=0.933, OR=1.026, 95%CI=0.909-1.159). However, statistically significance was evident in comparison of genotype CC vs GG in cancer risk ($P_H$=0.586, OR=2.854, 95%CI= 1.413-5.763), especially in colorectal cancer ($P_H$=0.481, OR=4.527, 95%CI= 1.664- 12.315). Conclusions: Genotype CC of rs1800947 in the CRP gene is strongly associated with increased cancer risk, particularly in colorectal cancer.


C-reactive protein gene;rs1800947;colorectal cancer;risk factor


  1. Wen W., Cai Q, Xiang YB, et al (2008). The modifying effect of C-reactive protein gene polymorphisms on the association between central obesity and endometrial cancer risk. Cancer, 112, 2409-16.
  2. Tsilidis KK, Helzlsouer KJ, Smith MW, et al (2009). Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer. Cancer Cause Control, 20, 1739-51.
  3. Xu M, Zhu M, Du Y, et al (2013). Serum C-reactive protein and risk of lung cancer: a case-control study. Med Oncol, 30, 1-6.
  4. Ueno H, Okada S, Okusaka T, Ikeda M (2000). Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology, 59, 296-301.
  5. Yang SH, Huang CJ, Chang SC, Lin JK (2011). Association of C-reactive protein gene polymorphisms and colorectal cancer. Ann Surg Oncol, 18, 1907-15.
  6. Shimada H, Nabeya Y, Okazumi SI, et al (2003). Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol, 83, 248-52.
  7. Ognjanovic S, Yamamoto J, Saltzman B, et al (2010). Serum CRP and IL-6, genetic variants and risk of colorectal adenoma in a multiethnic population. Cancer Causes Control, 21, 1131-8.
  8. Pierce BL, Biggs ML, DeCambre M, et al (2009). C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older. Cancer Causes Control, 20, 1193-03.
  9. Poole EM., Bigler J, Whitton J, et al (2009). C-reactive protein genotypes and haplotypes, polymorphisms in NSAIDmetabolizing enzymes, and risk of colorectal polyps. Pharmacogenet Genom, 19, 113-20.
  10. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA: Cancer J Clini, 63, 11-30.
  11. Siemes C, Visser LE, Coebergh JW, et al (2006). C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clini Oncol, 24, 5216-22.
  12. Slattery ML, Curtin K, Poole E, et al (2011). Genetic variation in C-reactive protein in relation to colon and rectal cancer risk and survival. Int J Cancer, 128, 2726-34.
  13. Song CQ,Zhang JH,Shi JC, et al (2014). Bioinformatic prediction of SNPs within miRNA binding sites of inflammatory genes associated with gastric cancer. Asian Pac J Cancer Prev, 15, 937-42
  14. Suk HJ, Ridker PM, Cook NR, Zee RY (2005). Relation of polymorphism within the C-reactive protein gene and plasma CRP levels. Atherosclerosis, 178, 139-45.
  15. Lange LA, Carlson CS, Hindorff LA, et al (2006). Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. JAMA: J Am Med Assoc, 296, 2703-11.
  16. Kohler A, Eggers H, Kuczyk MA, Schrader AJ, Steffens S (2013). Utility of the serum CRP value for assessing the prognosis and therapeutic response of urological malignancies. Aktuel Urol, 44, 452-5.
  17. Koma Y, Onishi A, Matsuoka H, et al (2013). Increased red blood cell distribution width associates with cancer stage and prognosis in patients with lung cancer. PloS one, 8, 80240.
  18. Kong M, Lee C (2012). Genetic associations with C-reactive protein level and white blood cell count in the KARE study. Int J Immunogenet, 40, 120-5
  19. Li QQ, Lu ZH,Yang L, et al (2014). Neutrophil count and the inflammation-based glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy. Asian Pac J Cancer Prev, 15, 945-50
  20. Lin M, Huang J, Zhu J, Shen H (2013). Elevated pre-treatment levels of high sensitivity C-reactive protein as a potential prognosticator in patients with colorectal cancer. Exp Ther Med, 6, 1369.
  21. Maccio A, Lai P, Santona MC, et al (1998). High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol, 69, 248-52.
  22. Motoyama S, Miura M, Hinai Y, et al (2009). C-reactive protein 1059G>C genetic polymorphism influences serum C-reactive protein levels after esophagectomy in patients with thoracic esophageal cancer. J Am Coll Surgeons, 209, 477-83.
  23. Motoyama S, Nakatsu T, Miura M, et al (2013). A CRP genetic polymorphism associated with the tumoral expression of CRP in esophageal cancer. Surg Today, 43, 339-40.
  24. Guo YZ, Pan L, Du CJ (2013). Association between C-reactive protein and risk of cancer:a meta-analysis of prospective cohort studies. Asian Pac J Cancer Prev, 14, 243-8
  25. Gabay C, Kushner I (1999). Acute-phase proteins and other systemic responses to inflammation. New Engl J Med, 340, 448-54.
  26. Chaturvedi AK, Caporaso NE, Katki HA, et al (2010). C-reactive protein and risk of lung cancer. J Clin Oncol, 28, 2719-26.
  27. Degenhardt K, Mathew R, Beaudoin B, et al (2006). Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell, 10, 51-64.
  28. Disis ML. (2010). Immune regulation of cancer. J Clin Oncol, 28, 4531-8.
  29. Hedges LV, Vevea JL. (1998). Fixed-and random-effects models in meta-analysis. Psychological methods, 3, 486.
  30. Huang C J, Teng HW, Chien CC, Lin JK, Yang SH (2013). Prognostic significance of C-reactive protein polymorphism and KRAS/BRAF in synchronous liver metastasis from colorectal cancer. PloS one, 8, 65117.
  31. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J (2006). Assessing heterogeneity in meta-analysis: Q statistic or $I^{2}$ index? Psychological methods, 11, 193.
  32. Khreiss T, Jozsef L, Hossain S, et al (2002). Loss of pentameric symmetry of C-reactive protein is associated with delayed apoptosis of human neutrophils. J Biol Chem, 277, 40775-81.
  33. Kivimaki M, Lawlor DA, Smith GD, et al (2007). Variants in the CRP gene as a measure of lifelong differences in average c-reactive protein levels the cardiovascular risk in young Finns Study, 1980-2001. Am J Epidemiol, 166, 760-4.
  34. ABunt SK., Yang L, Sinha P, et al (2007). Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res, 67, 10019-26.
  35. Canna K, McArdle PA, McMillan DC, et al (2005). The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer, 92, 651-4.

Cited by

  1. Prognostic Value of C-Reactive Protein in Esophageal Cancer: a Meta-analysis vol.15, pp.19, 2014,